Related Experiment Video

Updated: Jul 16, 2026

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines

Antoinette Hollestelle1, Fons Elstrodt, Jord H A Nagel

  • 1Department of Medical Oncology, Josephine Nefkens Institute Be414, Erasmus MC, P.O. Box 1738, 3000 DR Rotterdam, the Netherlands.

Molecular Cancer Research : MCR
|February 23, 2007
PubMed

Insights

Mutations in phosphatidylinositol-3-OH kinase (PI3K) and RAS pathways are common in breast cancers. These signaling pathways show mutual exclusivity in breast cancer, unlike in colorectal cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Constitutive activation of phosphatidylinositol-3-OH kinase (PI3K) and RAS signaling pathways is crucial in tumor formation.
  • Frequent genetic alterations in PI3K and RAS pathway components are observed across various human cancers.

Purpose of the Study:

  • To investigate the mutation status of key genes in the PI3K and RAS pathways in human breast cancer cell lines.
  • To compare the mutation spectra and pathway interactions in breast cancer with those in other cancer types, such as colorectal cancer.

Main Methods:

  • Detailed sequence analysis of PTEN, PIK3CA, KRAS, HRAS, NRAS, and BRAF genes.
  • Analysis of 40 human breast cancer cell lines.

Main Results:

  • A significant proportion of breast cancer cell lines exhibited mutations in the PI3K (54%) and RAS (25%) pathways.
  • Mutation spectra for PIK3CA, KRAS, and BRAF in breast cancer cell lines were comparable to those in colorectal cancers.
  • Mutational activation of the PI3K pathway was mutually exclusive with RAS pathway activation in breast cancer, a finding distinct from colorectal cancers.

Conclusions:

  • The PI3K and RAS pathways are frequently altered in breast cancer.
  • Breast cancer exhibits a unique pattern of mutual exclusivity between PI3K and RAS pathway activation, suggesting tissue-specific regulatory mechanisms.
  • These findings highlight potential differences in oncogenic signaling between breast epithelium and other tissues.

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...